Marina Mencinger

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias et al. · The Lancet · 2020 · 787 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 514 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Expression Patterns of the Human Sarcoma-Associated GenesFUSandEWSand the Genomic Structure ofFUS

Pierre Åman, Ioannis Panagopoulos, Carin Lassen et al. · Genomics · 1996 · 163 citations · Full text

Medicine, Genetics, Molecular Genetics +16

Fusion of the RBP56 and CHN genes in extraskeletal myxoid chondrosarcomas with translocation t(9;17)(q22;q11)

Ioannis Panagopoulos, Marina Mencinger, Claudia U. Dietrich et al. · Oncogene · 1999 · 87 citations

Medicine, Genetics, Molecular Genetics +8

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

Enrique Grande, José Ángel Arranz, Maria De Santis et al. · The Lancet Oncology · 2023 · 55 citations

Medicine, Oncology, Pharmacology +13